Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ricketts

Showing results (201-210 of 221) with videos related to

Pageof 23
Sort By:
EMBO Molecular Medicine|March 29, 2023
TFEB and TFE3 drive kidney cystogenesis and tumorigenesisChiara Di Malta, Angela Zampelli, Letizia Granieri, et al.
Nature Genetics|February 7, 2012
Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibilityDewi Astuti, Mark R Morris, Wendy N Cooper, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 24, 2023
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinomaMartin Lang, Laura S Schmidt, Kelli M Wilson, et al.
Oncotarget|September 30, 2016
Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutationSuraj Peri, Elena Caretti, Rossella Tricarico, et al.
Human Mutation|October 6, 2009
Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHDChristopher J Ricketts, Julia R Forman, Eleanor Rattenberry, et al.
Science Signaling|January 6, 2021
Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancerDaniel R Crooks, Nunziata Maio, Martin Lang, et al.
Nature Communications|August 23, 2024
Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and BenchmarkLuopin Wang, Aryamav Pattnaik, Subhransu Sekhar Sahoo, et al.
Biorxiv : the Preprint Server for Biology|January 20, 2025
Impaired oxidative phosphorylation drives primary tumor escape and metastasisEmily N Arner, Erin Q Jennings, Daniel R Crooks, et al.
Molecular Cancer Therapeutics|October 14, 2024
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82Susana S Najera, Christopher J Ricketts, Laura S Schmidt, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2024
Toward a CRISPR-based mouse model of <i>Vhl</i>-deficient clear cell kidney cancer: Initial experience and lessons learnedLaura A Stransky, Wenhua Gao, Laura S Schmidt, et al.
Pageof 23

Showing results (201-210 of 221) with videos related to

Sort By:
Pageof 23
EMBO Molecular Medicine|March 29, 2023
TFEB and TFE3 drive kidney cystogenesis and tumorigenesisChiara Di Malta, Angela Zampelli, Letizia Granieri, et al.
Nature Genetics|February 7, 2012
Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibilityDewi Astuti, Mark R Morris, Wendy N Cooper, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 24, 2023
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinomaMartin Lang, Laura S Schmidt, Kelli M Wilson, et al.
Oncotarget|September 30, 2016
Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutationSuraj Peri, Elena Caretti, Rossella Tricarico, et al.
Human Mutation|October 6, 2009
Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHDChristopher J Ricketts, Julia R Forman, Eleanor Rattenberry, et al.
Science Signaling|January 6, 2021
Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancerDaniel R Crooks, Nunziata Maio, Martin Lang, et al.
Nature Communications|August 23, 2024
Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and BenchmarkLuopin Wang, Aryamav Pattnaik, Subhransu Sekhar Sahoo, et al.
Biorxiv : the Preprint Server for Biology|January 20, 2025
Impaired oxidative phosphorylation drives primary tumor escape and metastasisEmily N Arner, Erin Q Jennings, Daniel R Crooks, et al.
Molecular Cancer Therapeutics|October 14, 2024
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82Susana S Najera, Christopher J Ricketts, Laura S Schmidt, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2024
Toward a CRISPR-based mouse model of <i>Vhl</i>-deficient clear cell kidney cancer: Initial experience and lessons learnedLaura A Stransky, Wenhua Gao, Laura S Schmidt, et al.
Pageof 23